Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Kiniksa Pharmaceuticals, Ltd. | knsa-20210331xex32d1.htm |
| EX-31.2 - EX-31.2 - Kiniksa Pharmaceuticals, Ltd. | knsa-20210331xex31d2.htm |
| EX-31.1 - EX-31.1 - Kiniksa Pharmaceuticals, Ltd. | knsa-20210331xex31d1.htm |
| EX-10.4 - EX-10.4 - Kiniksa Pharmaceuticals, Ltd. | knsa-20210331xex10d4.htm |
| EX-10.3 - EX-10.3 - Kiniksa Pharmaceuticals, Ltd. | knsa-20210331xex10d3.htm |
| EX-10.2 - EX-10.2 - Kiniksa Pharmaceuticals, Ltd. | knsa-20210331xex10d2.htm |
| EX-10.1 - EX-10.1 - Kiniksa Pharmaceuticals, Ltd. | knsa-20210331xex10d1.htm |
| 10-Q - 10-Q - Kiniksa Pharmaceuticals, Ltd. | knsa-20210331x10q.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Mark Ragosa, Chief Financial Officer of Kiniksa Pharmaceuticals, Ltd. (the “Company”), hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
(1) The Quarterly Report on Form 10-Q of the Company for the period ended March 31, 2021 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
May 6, 2021 | /s/ Mark Ragosa |
| Mark Ragosa |
| Chief Financial Officer (Principal Financial Officer) |
| |